Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07XSN
|
|||
| Former ID |
DAP000644
|
|||
| Drug Name |
Cytarabine
|
|||
| Synonyms |
Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Approved | [1], [2], [3] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Upjohn Corporation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H13N3O5
|
|||
| Canonical SMILES |
C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
|
|||
| InChI |
1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
|
|||
| InChIKey |
UHDGCWIWMRVCDJ-CCXZUQQUSA-N
|
|||
| CAS Number |
CAS 147-94-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5877, 598052, 829245, 3260118, 7847236, 7885952, 7979015, 8153933, 11528303, 11533128, 12146044, 14774115, 15196510, 24858315, 24892435, 26527898, 26719755, 29215144, 29225249, 46386862, 46505879, 47193873, 47573376, 48415837, 49831046, 50105698, 53787662, 56310997, 56311029, 56312269, 56312943, 56313129, 56313612, 76890970, 83110442, 87558791, 90341066, 92308449, 92309014, 93166529, 93167157, 103210760, 103986361, 104253284, 104311532, 117529237, 118048876, 124648720, 124757405, 124799562
|
|||
| ChEBI ID |
CHEBI:28680
|
|||
| ADReCS Drug ID | BADD_D00560 ; BADD_D00561 | |||
| SuperDrug ATC ID |
L01BC01
|
|||
| SuperDrug CAS ID |
cas=000147944
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Parabacteroides
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Parabacteroides was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Bifidobacterium was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Atopobium
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Atopobium was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Collinsella
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Collinsella was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Adlercreutzia
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Adlercreutzia was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Citrobacter
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Citrobacter was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Klebsiella
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Klebsiella was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Blautia was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Clostridium
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Clostridium was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Coprococcus
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Coprococcus was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Dorea
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Dorea was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Lachnospira
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Lachnospira was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Oscillospira
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Oscillospira was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Roseburia
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Roseburia was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
|
Studied Microbe: Ruminococcus
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Ruminococcus was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Enterococcus was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Tissierellales | ||||
|
Studied Microbe: Anaerococcus
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Anaerococcus was decreased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
|
Studied Microbe: Megasphaera
Show/Hide Hierarchy
|
[4], [5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Non-Hodgkin's lymphoma | |||
| Description | The abundance of Megasphaera was increased by Combination of carmustine, etoposide, aracytine and melphalan (p < 0.05). | |||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Herpes simplex virus DNA polymerase UL30 (HSV UL30) | Target Info | Inhibitor | [6] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4827). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071471. | |||
| REF 3 | Incorporation of gemcitabine and cytarabine into DNA by DNA polymerase beta and ligase III/XRCC1. Biochemistry. 2010 Jun 15;49(23):4833-40. | |||
| REF 4 | Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther. 2015 Sep;42(5):515-28. | |||
| REF 5 | Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome. 2018 May 22;6(1):92. | |||
| REF 6 | Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.